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図１　Cell cycle analyses of adipocytes isolated from various adipose tissues of LETO and OLETF rats. LETO, LETO rats；
OLETF, OLETF rats；PIO, OLETF rats treated with pioglitazone；HX531, OLETF rats treated with HX531. EPI, epididymal；
RET, retroperitoneal；MES, mesenteric；SUB, subdermal；BAT, brown adipose tissues. Nuclear DNA was stained with 50µg/
ml propidium iodide and stained cells were analyzed on a laser scanning cytometer.（転載許可を得て文献10より一部改変して引用）
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図２　Human visceral preadipocytes (HVP) induced with dexamethasone, insulin, indomethacin and isobutyl-methylxanthine 
supplemented with 0.1% v/v DMSO (DMSO group), 10µM pioglitazone, (PIO group), and 2.5µM HX531 (HX531 group). (A) 
Oil-red O staining. (B) Western blot analyses.；Skp2, F-box protein S-phase kinase-associated protein 2；G0S2, G0/G1 switch gene 
2；AMPK, AMP-activated protein kinase；TAK1, TGF-β activated kinase 1；CAMKK2, calcium/calmodulin-dependent protein 
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図３　Hypothetical schema of action mechanisms of HX531 
inhibiting adipocyte hypertrophy and hyperplasia. The action 
of HX531 is compared with pioglitazone (arrows). （転載許可
を得て文献10より引用）
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